Literature DB >> 1630876

Direct measurement of probenecid and its glucuronide conjugate by means of high pressure liquid chromatography in plasma and urine of humans.

T B Vree1, E W Beneken Kolmer.   

Abstract

Probenecid with its phase-I metabolites, and phase-II glucuronide conjugate can be analysed by a gradient high pressure liquid chromatographic method. Probenecid glucuronide in plasma with pH 7.4 is not stable and declines to 10% of the original value within 6 h (t1/2 approximately 1 h). Probenecid glucuronide is stable in urine with pH 5.0, moderately unstable at pH 6.0 (t1/2 approximately 10 h), and unstable at pH 8.0 (t1/2 approximately 0.5 h). Probenecid glucuronide is stable in water and 0.01 mol/l phosphoric acid in the autosampler of the high pressure liquid chromatograph. The decrease in concentration in water is 5.5% during 9 h and 0% in diluted acid. Probenecid glucuronide and the phase-I metabolites were not detectable in plasma. The main compound in fresh urine is the phase-II conjugate probenecid glucuronide (62% of a 500 mg dose); the phase-I metabolites are present and only a trace of probenecid is present. The percentage of the dose of the phase-I metabolites varies between 5 and 10, while hardly any probenecid is excreted unchanged (0.33%).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1630876     DOI: 10.1007/bf01962691

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  44 in total

1.  Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout.

Authors:  A B GUTMAN; T F YU
Journal:  Am J Med       Date:  1957-10       Impact factor: 4.965

2.  Direct determination of codeine, norcodeine, morphine and normorphine with their corresponding O-glucuronide conjugates by high-performance liquid chromatography with electrochemical detection.

Authors:  C P Verwey-van Wissen; P M Koopman-Kimenai; T B Vree
Journal:  J Chromatogr       Date:  1991-10-04

3.  High-performance liquid chromatographic method for the simultaneous quantitation of diflunisal and its glucuronide and sulfate conjugates in human urine.

Authors:  G R Loewen; J I Macdonald; R K Verbeeck
Journal:  J Pharm Sci       Date:  1989-03       Impact factor: 3.534

4.  pH-dependent rearrangement of the biosynthetic ester glucuronide of valproic acid to beta-glucuronidase-resistant forms.

Authors:  R G Dickinson; W D Hooper; M J Eadie
Journal:  Drug Metab Dispos       Date:  1984 Mar-Apr       Impact factor: 3.922

5.  The formation of beta-glucuronidase resistant glucuronides by the intramolecular rearrangement of glucuronic acid conjugates at mild alkaline pH.

Authors:  K A Sinclair; J Caldwell
Journal:  Biochem Pharmacol       Date:  1982-03-15       Impact factor: 5.858

6.  Reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of diflunisal and its glucuronides in serum and urine. Rearrangement of the 1-O-acylglucuronide.

Authors:  J Hansen-Møller; L Dalgaard; S H Hansen
Journal:  J Chromatogr       Date:  1987-09-04

7.  Pharmacokinetics, N1-glucuronidation, and N4-acetylation of sulfa-6-monomethoxine in humans.

Authors:  T B Vree; E W Beneken Kolmer; Y A Hekster; M Shimoda; M Ono; T Miura
Journal:  Drug Metab Dispos       Date:  1990 Nov-Dec       Impact factor: 3.922

8.  Metabolic formation of N- and O-glucuronides of 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid. Rearrangement of the 1-o-acyl glucuronide.

Authors:  F W Janssen; S K Kirkman; C Fenselau; M Stogniew; B R Hofmann; E M Young; H W Ruelius
Journal:  Drug Metab Dispos       Date:  1982 Nov-Dec       Impact factor: 3.922

9.  Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation.

Authors:  D R Abernethy; D J Greenblatt; B Ameer; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

10.  Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfamethomidine in humans.

Authors:  T B Vree; E W Beneken Kolmer; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1991-10-18
View more
  6 in total

1.  Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid. A pilot experiment.

Authors:  T B Vree; M Van den Biggelaar-Martea; E W Van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-08-20

2.  Probenecid inhibits the glucuronidation of indomethacin and O-desmethylindomethacin in humans. A pilot experiment.

Authors:  T B Vree; M van den Biggelaar-Martea; C P Verwey-van Wissen; E W van Ewijk-Beneken Kolmer
Journal:  Pharm World Sci       Date:  1994-02-18

3.  Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans.

Authors:  T B Vree; M van den Biggelaar-Martea; E W van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-06-18

4.  Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans.

Authors:  T B Vree; E W Van Ewijk-Beneken Kolmer; E W Wuis; Y A Hekster; M M Broekman
Journal:  Pharm World Sci       Date:  1993-10-15

5.  Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study.

Authors:  T B Vree; E W Van Ewijk-Beneken Kolmer; E W Wuis; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

6.  Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.

Authors:  T B Vree; M van den Biggelaar-Martea; C P Verwey-van Wissen
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.